← Stack analyses
Immune Stack (Thymosin α1 + Thymalin)
ImmunityComponents
Rationale
The thymic double: Tα1 (approved in 30+ countries, 1.6 mg SC twice weekly) as the continuously-dosed backbone, thymalin as the periodic course in the bioregulator tradition. Both target immune aging/rebalancing from the thymus side.
Evidence level
Tα1 has genuine regulatory review behind it; thymalin has the standard bioregulator profile. Together: plausible, unreplicated, unstudied as a pair.
Caution
Immune-modulating peptides in people with actual immune disease is a physician conversation, not a stack decision. Low acute risk in healthy users; the opportunity cost is real immunology care when something is actually wrong.